TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22348910
Drug: Standard antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antifungal treatment
Study: 22348910
Drug: Standard antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antifungal treatment plus pessary capsules containing 200 mg GMH (twice a week for thirty days)
Study: 8777120
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (25 mg)
Study: 6668409
Drug: PGF2 alpha
Normalized name: Prostaglandin PGF2 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGF2 alpha gel 5 mg
Study: 6668409
Drug: PGF2 alpha
Normalized name: Prostaglandin PGF2 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGF2 alpha gel 2.5 mg
Study: 27521979
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200mg twice daily for eight weeks
Study: 10407522
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg and midazolam 0.05 mg/kg (group I)
Study: 10407522
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg and midazolam 0.1 mg/kg (group II)
Study: 7380107
Drug: Diet regulation
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet regulation and 0.5 g tolbutamide t.i.d. (N = 49)
Study: 7380107
Drug: Diet regulation
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet regulation and one placebo tablet t.i.d. (N = 48)
Study: 19732495
Drug: Tinidazole 1
Normalized name: tinidazole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 1 g
Study: 15142199
Drug: Rabeprazole (Proton-pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (Proton-pump inhibitor) for 4 weeks
Study: 10861309
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg daily for 2 years)
Study: 12126263
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg o.d.
Study: 12191747
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg o.d.
Study: 31913519
Drug: ubrogepant 100
Normalized name: ubrogepant 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ubrogepant 100 mg
Study: 10639847
Drug: Ivermectin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (6 mg)
Study: 27153360
Drug: Fulranumab 1
Normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab 1 mg (1 mgQ4 wk)
Study: 27153360
Drug: Fulranumab 3
Normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab 3 mg (3 mgQ4 wk)
Study: 25826143
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract (1000 mg capsule, 7 days/week for 6 months)
Study: 25826143
Drug: Placebo (noncaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (noncaloric capsule, 7 days/week for 6 months)
Study: 19213793
Drug: UK-500,001 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-500,001 0.1 mg b.i.d.
Study: 19213793
Drug: UK-500,001 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-500,001 0.4 mg b.i.d.
Study: 17227996
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1200 mg of elemental calcium daily for 4 years)
Study: 11558856
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 mg, once daily)
Study: 9499281
Drug: Cefoxitin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (100 mg/kg/24 h)
Study: 9499281
Drug: Ceftizoxime (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime (100 mg/kg/24 h)
Study: 19239460
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dutasteride and tamsulosin
Study: 16432269
Drug: 10-mg rizatriptan
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg rizatriptan orally disintegrating tablet with water (ODTc)
Study: 16432269
Drug: 10-mg rizatriptan
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg rizatriptan orally disintegrating tablet without water (ODTs)
Study: 16432269
Drug: 10-mg rizatriptan
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg rizatriptan tablet
Study: 8703457
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (F) 1 microgram/kg
Study: 1393074
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of 1% lignocaine at 20 degrees C
Study: 27003829
Drug: Optimal doses
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal doses of renin-angiotensin system blockers (monotherapy or dual blockade)
Study: 27003829
Drug: Renin-angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system blockers treatment
Study: 16472283
Drug: moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: moxifloxacin 400 mg once daily for 7 days
Study: 15290734
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g MaxEPA (omega-3 fish oils)
Study: 15290734
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg copper
Study: 11263764
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training (50-70% of repetition maximum, all major muscle groups, twice a week)
Study: 3548440
Drug: Adenosine (5.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (5.1 mg/min)
Study: 9146328
Drug: Duraflo II
Normalized name: Duraflor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duraflo II heparin-coated circuit (n = 10)
Study: 9146328
Drug: Carmeda BioActive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmeda BioActive Surface heparin-coated circuit (n = 10)
Study: 2885344
Drug: Buspirone 10
Normalized name: busPIRone 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 10 to 30 mg daily
Study: 2885344
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 to 30 mg daily
Study: 21523338
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg QD
Study: 17936366
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg daily for 90 days)
Study: 29494855
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional secondary preventive therapy for ischemic stroke)
Study: 15234407
Drug: mibefradil 50
Normalized name: mibefradil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mibefradil 50 mg
Study: 15234407
Drug: mibefradil 100
Normalized name: mibefradil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mibefradil 100 mg/day
Study: 3144919
Drug: Subdermal estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subdermal estradiol pellets (25 mg, n = 10)
Study: 21255977
Drug: Nutricia preOp
Normalized name: propylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutricia preOp (400 mL; 50.4 g carbohydrates; 260 mOsm/kg)
Study: 21255977
Drug: Roosvicee Original
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roosvicee Original (400 mL; 48 g carbohydrates; 805 mOsm/kg)
Study: 15499622
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (verum)
Study: 9659026
Drug: 22 G
Normalized name: Empty Carpuject 2 mL 22 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 G cannula
Study: 9659026
Drug: 20 G
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 G cannula
Study: 2732892
Drug: Melatonin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (50 mg) administered at 7 pm
Study: 2732892
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at 9 am
Study: 2732892
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at 7 pm
Study: 2732892
Drug: Melatonin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (50 mg) administered at both times
Study: 30482192
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (up to six individual sessions over 3 weeks)
Study: 28486023
Drug: hemoglobin arm
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hemoglobin arm (maintaining hemoglobin between 85 and 100 g/L)
Study: 17129496
Drug: SIT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT with standardized house dust mite (HDM) vaccine
Study: 16513246
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hormone replacement therapy)
Study: 29997294
Drug: Oral norovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral norovirus vaccine (single dose)
Study: 25601335
Drug: Single fractions
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single fractions of 1.0 Gy applied two times a week, for a total dose of 6.0 Gy (total therapy time: 3 weeks)
Study: 23928902
Drug: Flublok® (trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flublok® (trivalent influenza vaccine)
Study: 21037989
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Gram-stained smear, rapid urease test, and culture methods
Study: 18218297
Drug: Moisture-resistant tablet
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisture-resistant tablet (dextran formulation)
Study: 18218297
Drug: Standard tablet
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tablet (lactose formulation)
Study: 9145877
Drug: Cefotaxime and
Normalized name: cefotaxime and beta-lactamase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime and Ofloxacin combination therapy
Study: 9145877
Drug: Ofloxacin monotherapy
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin monotherapy
Study: 9145877
Drug: Ofloxacin and
Normalized name: ofloxacin and ornidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin and Cefotaxime combination therapy
Study: 7679532
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of urapidil b.i.d. for 3 weeks (group L)
Study: 7679532
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg b.i.d. for 1 week followed by 30 mg b.i.d. for 2 weeks (group M)
Study: 7679532
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg b.i.d. for 1 week followed by 45 mg b.i.d. for 2 weeks (group H)
Study: 3497380
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (Connaught and Praxis)
Study: 23885519
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 300 microg (group M, n=20)
Study: 23885519
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 300 microg + bupivacaine 2 mg (group MB, n=20)
Study: 23885519
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 300 microg + bupivacaine 2 mg + fentanyl 25 microg (group MBF, n=20)
Study: 14583862
Drug: Dalbavancin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalbavancin (2 doses: 1100 mg IV once and 500 mg IV one week later)
Study: 7722124
Drug: heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin plus placebo
Study: 7722124
Drug: rt‐PA (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA (0.03 mg/kg body weight per h for 3 consecutive days) plus heparin
Study: 1974506
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg once daily (o.d.)
Study: 1974506
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg once daily (o.d.)
Study: 26880615
Drug: Indomethacin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (1.2 mg/kg)
Study: 26880615
Drug: Naproxen (4.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (4.2 mg/kg)
Study: 16037180
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of saline IV
Study: 9015519
Drug: Ivermectin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin, 400 micrograms/kg, 12 fortnightly doses
Study: 7039813
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (B/A, BCG, NFT)
Study: 3902388
Drug: Methylprednisolone (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (32 mg once daily)
Study: 25803759
Drug: Ultrasound-guided lumbar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided lumbar transforaminal epidural injection
Study: 25803759
Drug: Fluoroscopy-controlled lumbar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoroscopy-controlled lumbar transforaminal epidural injection
Study: 15854634
Drug: Trilostane +
Normalized name: TRILOSTANE
DrugBank: Trilostane (DB01108)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilostane + misoprostol (high-dose vaginal group: initial dose of 400 microg followed by 200 microg every 4 h)
Study: 15854634
Drug: Trilostane +
Normalized name: TRILOSTANE
DrugBank: Trilostane (DB01108)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilostane + misoprostol (vaginal-oral group: 400 microg vaginally followed by 200 microg orally every 4 h)
Study: 7591314
Drug: Pre-hospital treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital treatment with anistreplase followed by placebo after hospital admission (pre-hospital group; 2750 patients)
Study: 2144914
Drug: Twice per
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice per week (2X/week, n = 23)
Study: 7031861
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg bacampicillin twice daily
Study: 7031861
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg bacampicillin
Study: 7031861
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg bacampicillin
Study: 22976566
Drug: Topical ozonated
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ozonated olive oil (OZO) as an adjunct to scaling and root planing (SRP)
Study: 22976566
Drug: Topical chlorhexidine
Normalized name: chlorhexidine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical chlorhexidine gel as a monotherapy
Study: 17990196
Drug: EMDR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR treatment (eight weekly sessions)
Study: 17990196
Drug: EMDR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR treatment
Study: 15898028
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil (7.5 microg)
Study: 28207505
Drug: EBCA (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBCA (esomeprazole and colloidal bismuth pectin with clarithromycin and amoxicillin)
Study: 28207505
Drug: EBLA (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBLA (esomeprazole and colloidal bismuth pectin with levofloxacin and amoxicillin)
Study: 28207505
Drug: ELA (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELA (esomeprazole with levofloxacin and amoxicillin)
Study: 26025562
Drug: Buspirone 15
Normalized name: busPIRone 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 15 mg with melatonin-SR 3 mg
Study: 10721538
Drug: Antibiotics (specifically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (specifically amoxycillin as first line treatment)
Study: 9305231
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 200 micrograms once daily
Study: 9292184
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 200 micrograms once daily
Study: 18356656
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of dexamethasone
Study: 16554592
Drug: Intraluminal brachytherapy
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal brachytherapy using iridium-192 with a dose of 14 Gy
Study: 31394300
Drug: Adjunctive photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive photodynamic therapy (PDT) with full-mouth disinfection (FMD)
Study: 27798042
Drug: Prompt infertility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt infertility treatment
Study: 28486704
Drug: 6-month lifestyle
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month lifestyle intervention programme preceding infertility treatment
Study: 25853229
Drug: Weekly motivational
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly motivational counseling
Study: 19171726
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (gastric banding surgery)
Study: 8526243
Drug: Fluoxetine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, 20 mg/day for 5 weeks
Study: 30670421
Drug: 100-mg levofloxacin
Normalized name: levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100-mg levofloxacin dispersible tablets
Study: 30670421
Drug: Adult (250-mg)
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult (250-mg) levofloxacin tablets
Study: 28794898
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockers (ARBs)
Study: 8143996
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg, three times daily
Study: 8143996
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg, three times daily
Study: 8143996
Drug: Cisapride (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (both doses)
Study: 12536700
Drug: Conventional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medicine
Study: 28328389
Drug: Tablet-based hearing
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-based hearing screening method
Study: 23885614
Drug: Moxibustion at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion at Shenshu (BL 23) and Guanyuan (CV 4) for 15 min once daily for 5 weeks after training.
Study: 6363970
Drug: Peripheral anticholinergic
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral anticholinergic therapy
Study: 30094695
Drug: Cocaine users
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine users and injection drug users
Study: 19337246
Drug: Esophageal capsule
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esophageal capsule endoscopy (ECE)
Study: 17786387
Drug: Intravenous ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ATP infusions at doses of 20 microg kg(‐1) min(‐1), 25-40 microg kg(‐1) min(‐1), and 45-50 microg kg(‐1) min(‐1)
Study: 15612969
Drug: Purified trivalent
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified trivalent split-virus vaccine injections
Study: 9853844
Drug: Recombinant follicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant follicle stimulating hormone (rFSH, Puregon)
Study: 2904312
Drug: Prazosin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (5 mg every 8 hours)
Study: 25161155
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg simvastatin
Study: 27344670
Drug: PBM application
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM application using a 30 J/cm(2) dose
Study: 15867169
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg/d
Study: 16602839
Drug: mezlocillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin (3 x 2 g/d)
Study: 10913939
Drug: rhEPO (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO (40 U/kg at a constant infusion rate for 30 min, starting 15 min before TRH injection)
Study: 9044441
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement treatment
Study: 4054198
Drug: Meclonazepam 1
Normalized name: clonazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclonazepam 1 mg
Study: 4054198
Drug: Meclonazepam 2
Normalized name: clonazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclonazepam 2 mg
Study: 4054198
Drug: Meclonazepam 4
Normalized name: clonazepam 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclonazepam 4 mg
Study: 28068460
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment for 12 weeks
Study: 8814098
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 700 mg/day
Study: 8814098
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 600 mg/day